Protagonist Therapeutics, Inc. (PTGX)

Bosun Asset Management LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securi...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from th...

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 11.6% in the undefined quarter, according to the company i...

Aviva PLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 28.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchang...

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.54 per share a year ago....

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was s...

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the...

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations....

Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its or...